Literature DB >> 2318380

Ex vivo lipopolysaccharide-induced interleukin-1 secretion from murine peritoneal macrophages inhibited by probucol, a hypocholesterolemic agent with antioxidant properties.

G Ku1, N S Doherty, L F Schmidt, R L Jackson, R J Dinerstein.   

Abstract

Probucol, 4,4'-(isopropylidenedithio)bis(2,6-di-tert-butyl-phenol), has been shown to inhibit atherogenesis in genetically hypercholesterolemic (Watanabe) rabbits. Since atherosclerotic lesions contain macrophages capable of screting interleukin 1 (IL 1) and other cytokines that could contribute to the pathogenesis of the disease, we have investigated whether probucol affects IL 1 secretion. Resident peritoneal macrophages from mice dosed with probucol secreted 40-80% less IL 1 than macrophages from control animals when stimulated in vitro with lipopolysaccharide (LPS). The inhibitory effect of probucol was observed when IL 1 was assayed by the standard bioassay, the thymocyte proliferation assay, or a competitive IL 1 receptor binding assay. Probucol treatment had no effect on LPS-induced membrane IL 1 expression; secretion of tumor necrosis factor (TNF); Con A-induced splenic interleukin 2 (IL 2) and interleukin 3 (IL 3) release; and prostaglandin- or zymosan-induced secretion of prostacyclin, leukotriene C4, acid phosphatase, or superoxide anion. In contrast to the effect of oral administration, direct addition of probucol to macrophage cultures did not inhibit IL 1 release. Probucol administration did, however, inhibit the fall in serum zinc level induced by intravenous injection of LPS in zymosan-primed mice but had no effect on the LPS-induced increase in serum triglyceride levels, which indirectly confirms that probucol administration inhibits IL 1 but not TNF secretion. Paw granuloma induced in mice by heat-killed mycobacteria was inhibited by oral administration of probucol, an effect that may be attributable to inhibition of IL 1 secretion. Probucol neither reduced zymosan-induced liver granulomata in mice nor inhibited adjuvant-induced arthritis in rats. We suggest that inhibition of IL 1 secretion from macrophages by probucol contributes to its therapeutic effects in atherosclerosis and may also result in beneficial activity in some chronic inflammatory diseases.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2318380     DOI: 10.1096/fasebj.4.6.2318380

Source DB:  PubMed          Journal:  FASEB J        ISSN: 0892-6638            Impact factor:   5.191


  15 in total

Review 1.  The response-to-retention hypothesis of early atherogenesis.

Authors:  K J Williams; I Tabas
Journal:  Arterioscler Thromb Vasc Biol       Date:  1995-05       Impact factor: 8.311

Review 2.  New approaches to the prevention of atherosclerosis.

Authors:  M Naito; T Hayashi; A Iguchi
Journal:  Drugs       Date:  1995-09       Impact factor: 9.546

3.  Evidence for an additional intracellular site of action of probucol in the prevention of oxidative modification of low density lipoprotein. Use of a new water-soluble probucol derivative.

Authors:  S Parthasarathy
Journal:  J Clin Invest       Date:  1992-05       Impact factor: 14.808

4.  Augmentation of monocyte chemotactic protein-1 and mRNA transcript in chronic inflammatory states induced by potassium permanganate (KMnO4) in vivo.

Authors:  P Conti; M Reale; C Feliciani; S Frydas; M Trakatellis; F C Placido; I Cataldo; M Di Gioacchino; R C Barbacane
Journal:  Immunology       Date:  1997-10       Impact factor: 7.397

5.  Circulating levels of IL-1beta, a prothrombotic cytokine, are elevated in unstable angina versus stable angina.

Authors:  A D Simon; S Yazdani; W Wang; A Schwartz; L E Rabbani
Journal:  J Thromb Thrombolysis       Date:  2000-04       Impact factor: 2.300

6.  Dissociation of atherogenesis from aortic accumulation of lipid hydro(pero)xides in Watanabe heritable hyperlipidemic rabbits.

Authors:  P Witting; K Pettersson; A M Ostlund-Lindqvist; C Westerlund; M Wâgberg; R Stocker
Journal:  J Clin Invest       Date:  1999-07       Impact factor: 14.808

7.  Probucol inhibits not only the progression of atherosclerotic disease, but causes a different composition of atherosclerotic lesions in WHHL-rabbits.

Authors:  J H Braesen; U Beisiegel; A Niendorf
Journal:  Virchows Arch       Date:  1995       Impact factor: 4.064

8.  Probucol inhibits LPS-induced microglia activation and ameliorates brain ischemic injury in normal and hyperlipidemic mice.

Authors:  Yeon Suk Jung; Jung Hwa Park; Hyunha Kim; So Young Kim; Ji Young Hwang; Ki Whan Hong; Sun Sik Bae; Byung Tae Choi; Sae-Won Lee; Hwa Kyoung Shin
Journal:  Acta Pharmacol Sin       Date:  2016-06-27       Impact factor: 6.150

9.  Probucol inhibits neointimal thickening and macrophage accumulation after balloon injury in the cholesterol-fed rabbit.

Authors:  G A Ferns; L Forster; A Stewart-Lee; M Konneh; J Nourooz-Zadeh; E E Anggård
Journal:  Proc Natl Acad Sci U S A       Date:  1992-12-01       Impact factor: 11.205

10.  Abnormally high thromboxane biosynthesis in homozygous homocystinuria. Evidence for platelet involvement and probucol-sensitive mechanism.

Authors:  G Di Minno; G Davì; M Margaglione; F Cirillo; E Grandone; G Ciabattoni; I Catalano; P Strisciuglio; G Andria; C Patrono
Journal:  J Clin Invest       Date:  1993-09       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.